Loading…
Compugen Ltd
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -63.3% over 5Y.
today you would have $398.66▼ -60.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.53 | $1.53 | $1.98 | $0.72 | $4.30 | $12.11 | $5.96 | $2.17 | $2.50 | $5.10 | $6.39 | $8.33 | $8.95 | $4.92 | $4.95 | $4.92 | $4.85 | |
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Square root of 22.5 × earnings × book value — the two ceilings Graham proposed. Blind to intangibles, so it undervalues software and brands.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Median P/E of 22.4 among peers in the sector.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 13.3x operating profit, less net debt. Sees the business before its financing, so debt does not distort the comparison. Banks have no EBITDA — interest is their revenue, not a cost.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SIGASIGA Technologies Inc | $3.26 | — | 1.4x | — | -1.49% | $234.23M |
| RNAAtrium Therapeutics, Inc. | $13.64 | — | 1.0x | — | — | $233.32M |
| TNXPTonix Pharmaceuticals Holding Corp. | $13.59 | — | 1.0x | — | -81.82% | $233.08M |
| UTMDUtah Medical Products Inc | $72.77 |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Company description provided by Yahoo Finance.
| P/E |
| — |
| 4.0x |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| P/S | 48.4x | 2.0x | 4.9x | 5.3x | 8.3x | 61.9x | 506.7x | — | 7.3x | — | 366.3x | 34.8x | 33.8x | 103.4x | 743.9x | — | 149.7x | 637.6x |
| P/B | 4.1x | 1.4x | 2.5x | 2.7x | 0.8x | 3.5x | 8.5x | 10.6x | 3.5x | 4.4x | 4.1x | 3.6x | 3.9x | 11.5x | 10.2x | 8.8x | 5.9x | 5.8x |
| EPS | $0.38 | -$0.16 | -$0.21 | -$0.39 | -$0.41 | -$0.37 | -$0.43 | -$0.41 | -$0.72 | -$0.62 | -$0.40 | -$0.26 | -$0.36 | -$0.38 | -$0.35 | -$0.22 | -$0.13 |
| Profit margin | -423.03% | 48.57% | -51.07% | -56.05% | -449.25% | -570.05% | -1484.90% | — | -126.96% | — | -4425.00% | -217.34% | -89.71% | -396.82% | -5631.40% | — | -646.01% | -1532.40% |
| ROE | -32.06% | 34.40% | -25.92% | -28.61% | -43.38% | -32.06% | -24.79% | -71.34% | -60.68% | -126.52% | -49.60% | -22.43% | -10.45% | -44.16% | -77.12% | -61.30% | -25.47% | -13.98% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Not the average of the seven numbers above. Four of the seven start from the same earnings per share — Graham, Lynch, sector multiples and its own history — so averaging all seven would let one input count four times and drown out the others. Instead each family produces one number, and the fair price is the average of the families that answered. A family with two working formulas contributes their average, not two votes.
4 methods answered, across 3 families.
Every formula reads the same reported statements and they can be wrong together. The margin is room for that.
+134.3% from the average.
These are models, not forecasts, and not investment advice. Change one assumption and the number changes with it — that is a property of valuation, not a defect of this page.
| 22.2x |
| 1.9x |
| 1.70% |
| 8.76% |
| $231.69M |
| SYSo-Young International Inc. | $2.40 | — | 1.1x | — | -15.04% | $240.91M |
| ELMDElectromed, Inc. | $27.57 | 21.2x | 4.3x | — | 23.26% | $230.66M |